Treatment outcomes of patients with acinetobacter infection : comparison between polymyxin versus non polymyxin based therapy
Background: The growing resistance of Acinetobacter to almost all commercially available antibiotics is of major concern. Limited therapeutic options are currently available. Objectives: The aim of the study was to compare the efficacy of sulbactam regime to that of polymyxin B in the treatment A...
Saved in:
Main Author: | |
---|---|
Format: | Thesis |
Language: | English |
Published: |
2019
|
Subjects: | |
Online Access: | http://eprints.usm.my/49557/1/Aakil%20Jeewoody-24%20pages.pdf http://eprints.usm.my/49557/ |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Background: The growing resistance of Acinetobacter to almost all commercially available
antibiotics is of major concern. Limited therapeutic options are currently available.
Objectives: The aim of the study was to compare the efficacy of sulbactam regime to that of
polymyxin B in the treatment Acinetobacter infection.
Methods: This was a retrospective study of case records over one year period (1st January 2018
to 31st December 2018) at the Hospital Universiti Sains Malaysia. Patients of least 18 years old,
with clinical and microbiological evidence of Acinetobacter infection, were enrolled in the study.
Results: 34 patients received polymyxin and 38 received either ampicillin-sulbactam or
cefoperazone-sulbactam. 24 (63.2%) from the nonpolymyxin group achieved clinical success
while 13 (38.2%) achieved clinical success in the polymyxin group. 26 patients (68.4%) treated
with nonpolymyxin achieved microbiological success compared to 18 (52.9%) treated with
polymyxin. Mortality was lower in the nonpolymyxin group with 17 deaths (44.7%) compared
to 23 deaths (67.6%) in the polymyxin group. Multiple logistic regression showed that
microbiological failure was significantly associated with 30 days in patient mortality.
Conclusion: The most important finding of our study is that sulbactam appears to have a better
efficacy compared to polymyxin in treating Acinetobacter infection. |
---|